Epic Sciences Enters into Collaboration with Q2 Solutions to Expand Liquid Biopsy Capabilities

Epic’s Comprehensive Cancer Profiling™ now includes TruSight® Oncology 500

Epic Sciences, Inc. today announced it has entered into a global collaboration with Q2 Solutions®, a leading clinical trial laboratory services organization,to offer Illumina®’s TruSight Oncology 500 liquid biopsy test to Epic’s global biopharmaceutical customers.  The addition of TruSight Oncology 500 to Epic’s portfolio of testing capabilities, brings ctDNA analysis to Epic’s CTC-based platform that enumerates and characterizes circulating tumor cells (CTCs). TruSight Oncology 500 enables analysis of circulating tumor DNA (ctDNA) of the full exonic sequence of over 500 genes in key cancer-related pathways, and includes identifying single-nucleotide variants, indels, copy number variants, DNA fusions, microsatellite instability (MSI) and tumor mutational burden (TMB).

“From a single blood draw, Epic can now perform Comprehensive Cancer Profiling that identifies CTCs with unmatched sensitivity, provides in depth characterization of individual CTCs using genomic, proteomic and morphological tools and delivers a comprehensive genomic profile of the patient’s ctDNA that includes all known biomarkers and mutations associated with current cancer therapies,” said Jim Walther, Vice President Business Development and Biopharma Strategic Partnerships, Epic Sciences. “This molecular information is critical to understanding the current state of a patient’s disease and offers the ability to monitor the cancer status, mechanism of action, and their response to a specific therapy. The combination of CTCs and ctDNA is a comprehensive solution designed to meet the growing needs of our pharmaceutical partners as they seek to develop life-changing therapies.”

“We are excited to partner with Epic Sciences by offering the capabilities of our in-house Illumina TruSight Oncology 500 liquid biopsy test,” said Kellie Yarnell, VP, Genomic Laboratories, Q2 Solutions. “This collaboration allows for the ability to better evaluate and deliver the optimal treatment for cancer patients and we are honored to play a role in this.”

About Comprehensive Cancer Profiling

Epic Sciences’ Comprehensive Cancer Profiling provides a multi-technology approach to liquid biopsy from a single blood draw to complete several types of analyses. The company leverages its proven and proprietary CTC capabilities. Our enrichment-free approach reveals both genotypic and phenotypic insights and minimizes the risk of CTCs being missed. By combining CTC technology with ctDNA and immune cell analysis we enable a comprehensive analysis that is both minimally invasive and highly accurate.

About Epic Sciences 

Epic Sciences, Inc. is developing novel diagnostics to guide therapy selection and monitor disease progression thereby personalizing and advancing the treatment and management of prostate and breast cancer. The company’s approach, Comprehensive Cancer Profiling, leverages proven and proprietary CTC capabilities, and adds ctDNA and immune cell analysis, to provide more complete data allowing more efficient analysis and clearer insights.  The company’s CTC based diagnostic test, Oncotype DX   AR-V7 Nucleus Detect® test, is the first and only Medicare reimbursed liquid biopsy for metastatic prostate cancer and is available to oncologists and urologists from Exact Sciences. Today Epic Sciences partners with leading pharmaceutical companies and major cancer centers around the world to improve patient outcomes by providing clinicians with efficient information to guide treatment plans. Epic Sciences is headquartered in San Diego. Further information is available on the company’s website, Stay in touch on LinkedIn, Facebook, or on Twitter @EpicSciences.

About Q2 Solutions®

 Q2 Solutions is a leading global clinical trial laboratory services organization providing comprehensive testing, project management, supply chain, biorepository, biospecimen and consent tracking solutions. Leveraging our next generation technologies, we deliver agile and precise services designed to meet the diverse needs of our clients.  We provide scientific expertise and innovative solutions for ADME, bioanalytical, genomics, vaccines and central laboratory services, including flow cytometry, anatomic pathology, immunoassay, molecular and companion diagnostics, with meticulous regional and global clinical trial implementation support and high-quality data delivery. At Q2 Solutions, our work is rooted in research, grounded in collaboration, and guided by our passion to turn the hope of patients and caregivers around the world into the help they need.  To learn more, visit  

“The Power of Clarity” is a registered trademark, and the stylized “e” and “Comprehensive Cancer Profiling” are trademarks of Epic Sciences, Inc. “Illumina” and “TruSight” are registered trademarks of Illumina, Inc.; Q2 Solutions is a registered trademark of Q Squared Solutions Holdings LLC.; and “IQVIA” is a registered trademark of IQVIA Inc.

Media Contacts: 

Martha Weckel, Epic Sciences,

Tor Constantino, IQVIA Corporate Communications,